These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29992287)

  • 1. Reply to the letter to the editor 'Anti-EGFR therapy in oesophagogastric cancer: precise but not enough' by M. Salati and S. Cascinu.
    Ruhstaller T; Langer R; Thuss-Patience P; Eisterer W; Stahl M
    Ann Oncol; 2018 Sep; 29(9):2018. PubMed ID: 29992287
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the letter to the editor 'Anti-EGFR therapy in oesophagogastric cancer: precise but not enough' by M. Salati and S. Cascinu.
    Ruhstaller T; Langer R; Thuss-Patience P; Eisterer W; Stahl M
    Ann Oncol; 2018 Sep; 29(9):2026. PubMed ID: 32138979
    [No Abstract]   [Full Text] [Related]  

  • 3. Is there a future for EGFR targeted agents in esophageal cancer?
    Ilson DH
    Ann Oncol; 2018 Jun; 29(6):1343-1344. PubMed ID: 29668836
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to letter: Neoadjuvant chemoradiotherapy or chemotherapy for esophageal cancer: what is the current evidence?
    A von Döbeln G; Klevebro F; Nilsson M
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30561611
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Letter: "Tumor Response and Lymph Node Status After Neoadjuvant Chemoradiotherapy for Esophageal Cancer".
    Robb WB; Mariette C
    Ann Surg; 2017 May; 265(5):e69-e70. PubMed ID: 28394794
    [No Abstract]   [Full Text] [Related]  

  • 6. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail.
    Meng X; Wang J; Sun X; Wang L; Ye M; Feng P; Zhu G; Lu Y; Han C; Zhu S; Liao Z; Yu J
    Radiother Oncol; 2013 Nov; 109(2):275-80. PubMed ID: 24128808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran.
    Anvari K; Sima HR; Seilanian Toussi M; Anvari A; Shahidsales S; Memar B; Aledavoud SA; Forghani MN; Abdollahi A; Ghaffarzadegan K
    Arch Iran Med; 2017 Apr; 20(4):240-245. PubMed ID: 28412829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
    Sclafani F; Roy A; Cunningham D; Wotherspoon A; Peckitt C; Gonzalez de Castro D; Tabernero J; Glimelius B; Cervantes A; Eltahir Z; Oates J; Chau I
    Ann Oncol; 2013 Dec; 24(12):3123-8. PubMed ID: 24146218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
    Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
    Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
    Ruhstaller T; Pless M; Dietrich D; Kranzbuehler H; von Moos R; Moosmann P; Montemurro M; Schneider PM; Rauch D; Gautschi O; Mingrone W; Widmer L; Inauen R; Brauchli P; Hess V
    J Clin Oncol; 2011 Feb; 29(6):626-31. PubMed ID: 21205757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
    Fu JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
    Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Letter: "Radiation Is Not a Solution for Suboptimal Surgery. A Response to the Conclusions Drawn From the Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma With or Without Neoadjuvant Chemoradiotherapy Study".
    van Lanschot JJB; Noordman BJ
    Ann Surg; 2019 Jul; 270(1):e14-e15. PubMed ID: 30247326
    [No Abstract]   [Full Text] [Related]  

  • 15. [Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
    Richter I; Dvořák J; Blüml A; Cermáková E; Bartoš J; Urbanec M; Sitorová V; Ryška A; Sirák I; Buka D; Ferko A; Melichar B; Petera J
    Klin Onkol; 2014; 27(5):361-6. PubMed ID: 25312714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
    Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
    J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is esophagectomy necessary for esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy].
    Fu J; Tan Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):983-986. PubMed ID: 30269316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
    van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
    Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant chemoradiotherapy does not negatively impact the postoperative quality of life of esophageal cancer patients].
    Luttke M; Nicolay NH
    Strahlenther Onkol; 2018 Aug; 194(8):794-796. PubMed ID: 29846752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.